newsfilter
← Latest News
Earnings Call Transcripts·

STEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - CASTLE BIOSCIENCES INC

  • Financial Performance:

    • Q3 revenue grew 24% year-over-year, with full-year revenue guidance raised to a midpoint of $385–$395 million (increased by $20 million).
    • Adjusted EBITDA for the year is projected at $12.7 million, with free cash flow from operations estimated at $19.7 million.
    • Cash and cash equivalents plus marketable securities stand at approximately $278 million, strengthening the balance sheet.
    • Q3 adjusted gross margin was strong at 77%, consistent with prior year levels.
  • Guidance and Future Outlook:

    • 2027 revenue guidance implies mid-single-digit volume growth, particularly for Melanoma (Decision DX) and TissueCypher.
    • Management expects continued profitability in 2027 with potential margin pressure in the mid-to-high 70s range for gross margins as the business scales.
    • Long-term goals focus on 2028–2030, aiming for the Advanced Atopic Dermatitis (AD) test to become a significant revenue contributor and the EIS (Sybase) technology to potentially surpass it.
    • Squamous Cell Carcinoma (SCC) reimbursement is modeled for recovery in 2028, contingent on Novitas finalization.
  • Business Segments and Product Lines:

    • TissueCypher (GI): Growth driven primarily by increased utilization among existing clinicians rather than new orders; focus remains on closing workflow gaps in gastroenterology practices and expanding sales force productivity to ~100 reps.
    • Decision DX (Melanoma): Targeting 60% market penetration (up from current 25–30%); growth is promotionally responsive, with sales force refocused to drive volume.
    • Advanced Atopic Dermatitis (AD): Strategic focus on securing Medicare coverage and a CPT crosswalk in early 2027 to trigger commercial payer coverage; current strategy involves measured volume growth to validate reimbursement pathways.
    • Pipeline: Development continues on the non-endoscopic "Tether Sponge" technology for Barrett's esophagus and an external collaboration with Sybase for Electrical Impedance Spectroscopy (EIS) technology.
  • Market and Competitive Landscape:

    • Commercial payer success has improved significantly, with strong utility evidence justifying appropriate payments, though Medicare Advantage plans still face some prior authorization hurdles.
    • TissueCypher adoption is gaining traction as large GI practices implement formal protocols and standing orders to standardize Barrett's esophagus care, reducing variability based on individual clinician knowledge.
    • Competitive landscape in non-endoscopic detection is evolving, with potential entrants (e.g., Lucid) entering the market; Castle views this as a potential long-term volume driver for the TissueCypher funnel if those devices successfully identify at-risk patients.
    • Melanoma market penetration is expected to hit a ceiling around 60% without new immunotherapy interventions, though potential upstream vaccine approvals could drive penetration to 80%+.
  • Risks and Challenges:

    • Reimbursement Uncertainty: Key risks include the finalization of Novitas' coverage decision for SCC (targeting 2028) and the potential CMS "gap fill" vs. "crosswalk" determination for the AD test, which could delay commercial scaling.
    • Workflow Fragmentation: In gastroenterology, a "breakage" exists between surgical staff performing biopsies and clinical staff ordering tests due to EMR silos and staff turnover, requiring active management to close.
    • R&D Capital Allocation: Investments in Tether Sponge and Sybase collaborations may temporarily pressure operating margins if scaled aggressively prior to reimbursement confirmation.
    • Market Volatility: Delays in Medicare Advantage (MA) claim approvals and potential CAC meeting timelines (e.g., for Lucid or SCC tests) could impact short-term revenue realization.
  • Management Commentary and Tone:

    • Tone was confident and pragmatic; CEO Derek Matzold expressed strong satisfaction with the company's profitability and balance sheet position ("strong position," "healthy growth").
    • Management emphasized a shift from "survival" to "strategic scaling," highlighting the importance of workflow integration and evidence generation over mere volume growth.
    • CEO noted that while the business is healthy without SCC revenue, regaining it is a critical strategic milestone.
    • Commentary on AD emphasized a "measured basis" for volume growth to ensure alignment with reimbursement milestones before 2028.
  • Analyst Questions and Answers:

    • ASP Drivers: Management attributes ASP growth to improved commercial payer payment success and Medicare Advantage resolution, not new pricing models; Medicare claims are forecasted at 100% payment rates.
    • New Clinician Adoption: Despite saturation in dermatology, GI remains a "greenfield" opportunity due to clinician education gaps; management expects healthy growth in first-time ordering clinicians.
    • Melanoma Guidance: Confirmed mid-single-digit volume growth as the baseline, contingent on promotional activity; noted that lack of upstream immunotherapy updates limits growth beyond 60% penetration.
    • AD Crosswalk Status: Submitted alternative crosswalk data to CMS to avoid "gap fill"; management anticipates a decision by December 2027 rates, with expectations for a favorable outcome based on similar RNA-based NGS tests.
    • SCC Timeline: Revised outlook for Squamous Cell Carcinoma to 2028, citing the uncertainty of Novitas' finalization timeline despite potential CAC meetings.
  • Other Key Points:

    • The TissueCypher sales force has recently expanded to approximately 100 reps, with new hires requiring a 6-month ramp-up for full productivity in complex GI territories.
    • Management highlighted the "standing order" protocol trend in GI practices as a key accelerator for adoption once early adopters prove the test's clinical value.
    • The company is actively managing the "flow" of patients through the GI system by automating EMR flagging for Barrett's esophagus codes to reduce reliance on manual staff intervention.
    • Sybase collaboration involves an "electrical impedance spectroscopy" highlighter pen technology; early data will dictate further R&D investment in 2027.
Company
CASTLE BIOSCIENCES INC
Keywords
CASTLE BIOSCIENCES INC